We are live on ! Find out more
HA

HHLR Advisors Portfolio holdings

AUM $1.67B
1-Year Est. Return 7.53%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+7.53%
3 Year Est. Return
+82.23%
5 Year Est. Return
+55.28%
10 Year Est. Return
–
AUM
$7.65B
AUM Growth
-$2.07B
Cap. Flow
-$890M
Cap. Flow %
-11.64%
Top 10 Hldgs %
69.25%
Holding
109
New
20
Increased
5
Reduced
15
Closed
24

Top Buys

Rank Stock Value
1
ONON icon
On Holding
ONON
+$561M
2
LEGN icon
Legend Biotech
LEGN
+$433M
3
CTKB icon
Cytek Biosciences
CTKB
+$206M
4
SE icon
Sea Limited
SE
+$101M
5
ERAS icon
Erasca
ERAS
+$97.4M

Top Sells

Rank Stock Value
1
ESGR
Enstar Group
ESGR
+$418M
2
PDD icon
Pinduoduo
PDD
+$398M
3
ZM icon
Zoom
ZM
+$398M
4
ABNB icon
Airbnb
ABNB
+$300M
5
UBER icon
Uber
UBER
+$188M

Sector Composition

Rank Sector Weight
1 Healthcare 57.57%
2 Consumer Discretionary 24.98%
3 Technology 6.63%
4 Communication Services 6.51%
5 Consumer Staples 1.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SHCO
26
DELISTED
Soho House & Co
SHCO
$46.1M 0.6%
+3,708,041
New +$46.3M
TIL icon
27
Instil Bio
TIL
$49.2M
$42.6M 0.56%
119,273
– –
BILI icon
28
Bilibili
BILI
$7.81B
$42.2M 0.55%
638,038
-1,360,233
-68% -$116M
TSM icon
29
TSMC
TSM
$1.96T
$40.2M 0.53%
360,495
– –
BZ icon
30
Kanzhun
BZ
$7.24B
$37.8M 0.49%
1,050,000
– –
ALGS icon
31
Aligos Therapeutics
ALGS
$26.4M
$36.7M 0.48%
94,603
+8,000
+9% +$3.16M
ARGX icon
32
argenx
ARGX
$55.4B
$36.2M 0.47%
120,000
-237,000
-66% -$75.1M
LYEL icon
33
Lyell Immunopharma
LYEL
$323M
$34.8M 0.45%
117,448
– –
AKRO
34
DELISTED
Akero Therapeutics
AKRO
$34.4M 0.45%
1,540,465
-116,208
-7% -$2.63M
KNSA icon
35
Kiniksa Pharmaceuticals
KNSA
$6.14B
$33.3M 0.44%
2,920,023
– –
NIO icon
36
NIO
NIO
$12B
$30.6M 0.4%
859,200
– –
LI icon
37
Li Auto
LI
$14.4B
$28.4M 0.37%
+1,080,000
New +$32.5M
HTHT icon
38
Huazhu Hotels Group
HTHT
$13.4B
$26.5M 0.35%
578,902
– –
FMTX
39
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$25.5M 0.33%
1,100,000
– –
ABNB icon
40
Airbnb
ABNB
$91.3B
$25M 0.33%
148,760
-1,963,877
-93% -$300M
ACMR icon
41
ACM Research
ACMR
$4.58B
$24.6M 0.32%
670,755
– –
PACB icon
42
Pacific Biosciences
PACB
$435M
$23.3M 0.3%
+911,039
New +$27M
ALLO icon
43
Allogene Therapeutics
ALLO
$583M
$20.6M 0.27%
800,000
– –
RGNX icon
44
Regenxbio
RGNX
$617M
$19.1M 0.25%
456,000
– –
SNOW icon
45
Snowflake
SNOW
$97.7B
$19.1M 0.25%
63,000
– –
PRLD icon
46
Prelude Therapeutics
PRLD
$366M
$18.2M 0.24%
583,333
– –
MLCO icon
47
Melco Resorts & Entertainment
MLCO
$2.2B
$17.4M 0.23%
1,698,877
– –
SOHU
48
Sohu.com
SOHU
$348M
$16.7M 0.22%
802,034
– –
DYN icon
49
Dyne Therapeutics
DYN
$4.21B
$16.2M 0.21%
1,000,000
– –
COIN icon
50
Coinbase
COIN
$43.3B
$15.9M 0.21%
+70,000
New +$17.2M
1
2
3 4 5

Similar funds

TFS
Thoroughbred Financial Services Brentwood, Tennessee $1.67B AUM 37.77% 1-Year Est. Return
GC
Garde Capital Seattle, Washington $1.67B AUM 13.9% 1-Year Est. Return
PA
Proem Advisors Dallas, Texas $1.68B AUM 199.97% 1-Year Est. Return
LCI
L1 Capital International Sydney NSW 2000, Australia $1.68B AUM 9.83% 1-Year Est. Return
JPM
JANA Partners Management New York $1.67B AUM 1.66% 1-Year Est. Return
NRI
NFP Retirement Inc Aliso Viejo, California $1.67B AUM 13.03% 1-Year Est. Return
CPO
Cerity Partners OCIO New York $1.67B AUM 13.22% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return

HHLR Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, HHLR Advisors held 109 positions worth $7.65B, down 21% from $9.71B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

HHLR Advisors withdrew a net $890M in Q3 2021, closing 24 positions and reducing 15 holdings. Its most notable exit was Enstar Group, an estimated $418M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 42% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, HHLR Advisors opened a new position in On Holding worth $481M.

  • HHLR Advisors's largest Q3 2021 buy was On Holding: 15,973,750 shares worth $481M.
  • HHLR Advisors added most to Legend Biotech in Q3 2021, an estimated $433M increase.
  • HHLR Advisors's biggest Q3 2021 reduction was Pinduoduo, cutting an estimated $398M.
  • HHLR Advisors fully exited Enstar Group in Q3 2021, selling an estimated $418M.
  • HHLR Advisors's ten largest holdings make up 69% of its $7.65B portfolio in Q3 2021.
  • HHLR Advisors opened 20 new positions and closed 24 in Q3 2021.
  • HHLR Advisors's portfolio value fell 21% quarter-over-quarter to $7.65B.

Based on HHLR Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.